Aldolase A deficiency

Aldolase A deficiency
Synonyms	Glycogen storage disease type XII
Pronounce	N/A
Specialty	N/A
Symptoms	Hemolytic anemia, myopathy, exercise intolerance
Complications	N/A
Onset	Childhood
Duration	Chronic
Types	N/A
Causes	Mutations in the ALDOA gene
Risks	Family history
Diagnosis	Genetic testing, enzyme assay
Differential diagnosis	Other glycogen storage diseases, muscle disorders
Prevention	N/A
Treatment	Supportive care, blood transfusions
Medication	N/A
Prognosis	Variable, depending on severity
Frequency	Rare
Deaths	N/A

Aldolase deficiency

Aldolase A deficiency, also known as Glycogen Storage Disease Type XII, is a rare inherited metabolic disorder affecting the enzyme aldolase A, which plays a crucial role in the glycolytic pathway. Its deficiency results in muscle weakness and hemolytic anemia. This article delves deep into the pathophysiology, clinical manifestations, diagnosis, and management of this condition.

Etiology

The deficiency arises from mutations in the ALDOA gene, which instructs the production of aldolase A enzyme. This enzyme is involved in the breakdown of glucose, a primary energy source.

Pathophysiology

Aldolase A primarily functions in:

• Skeletal muscles
• Red blood cells

Its role is to facilitate the glycolytic pathway, the primary process for glucose metabolism in anaerobic conditions. When Aldolase A is deficient:

• Muscles cannot efficiently produce energy, leading to muscle weakness or pain after physical activity.
• Red blood cells break down prematurely, causing hemolytic anemia.

Clinical Manifestations

• Myopathy - Muscle weakness, particularly following exercise.
• Hemolytic Anemia - Fatigue, pallor, jaundice, and shortness of breath.
• Dark urine due to the presence of hemoglobin (hemoglobinuria).
• Elevated levels of creatine kinase in the blood.

Diagnosis

• Blood Tests: To check for signs of hemolysis and evaluate muscle enzymes.
• Genetic Testing: For detecting mutations in the ALDOA gene.
• Muscle Biopsy: To evaluate muscle pathology and enzyme activity.
• Enzyme Assay: To measure aldolase activity in the blood.

Treatment

Currently, there's no cure, but management revolves around:

• Avoidance of strenuous exercise to prevent muscle damage.
• Monitoring and managing hemolytic anemia, possibly with blood transfusions.
• Physical therapy for muscle strength and endurance.

Prognosis

Most individuals have a mild form and can lead a normal life with appropriate management. Severe cases, though rare, might require frequent medical interventions.

Research

Research is ongoing to find better treatment modalities and understand the disease's full spectrum. Genetic therapies are of particular interest.

See Also

• Glycolytic Pathway
• Glycogen Storage Diseases
• Hemolytic Anemia

References

• Thompson, J. N., & Kapp, R. G. (1988). Aldolase A deficiency in man: A new syndrome. Journal of Neuropathology & Experimental Neurology.
• Sherwood, G., & Tarui, S. (1986). Glycogen storage disease type XII: a new variant in aldolase A in a young child with hemolytic anemia. Pediatric Research.

NIH genetic and rare disease info

• NIH info on Aldolase A deficiency

Aldolase A deficiency is a rare disease.